CareDx (CDNA) announced that AlloSure is now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney transplant. Both indications are approved by the New York State Clinical Laboratory Evaluation Program, demonstrating that AlloSure has met the most rigorous validation standards for laboratory developed tests.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA: